Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pretomanid + moxifloxacin + pyrazinamide + BMP-2
- Development stage
- Preclinical
- Lead developer
- TB Alliance
- Modality
- Hydrogel Systems → Drug Delivery Systems, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Local, Implantation
01
Overview
pretomanid + moxifloxacin + pyrazinamide + BMP-2 is an experimental therapeutic combination developed by researchers at The Second Affiliated Hospital of Zunyi Medical University for the localized treatment of spinal tuberculosis (Pott's disease). This multi-component system integrates a potent anti-tuberculosis antibiotic regimen—consisting of the nitroimidazole pretomanid, the fluoroquinolone moxifloxacin, and the nicotinamide analog pyrazinamide—with recombinant human Bone Morphogenetic Protein-2 (BMP-2). The therapy is typically delivered via a sustained-release carrier, such as a 3D-printed porous scaffold or a composite hydrogel, which is surgically implanted at the site of vertebral infection. This localized delivery strategy aims to achieve high regional concentrations of antibiotics to eradicate *Mycobacterium tuberculosis* while leveraging the osteoinductive properties of BMP-2 to facilitate the repair of bone defects and enhance spinal stability.
- Other names
- pretomanid + moxifloxacin + pyrazinamide + BMP-2
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)BMPR (Bone morphogenetic protein receptor)InhA
Beyond the preview
Go deeper on pretomanid + moxifloxacin + pyrazinamide + BMP-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pretomanid + moxifloxacin + pyrazinamide + BMP-2.